Will expand the company\'s research into regenerative medicine and cell therapy
Japanese pharmaceutical company Astellas has announced the launch of its new regenerative medicine business unit, which commenced operations on 1 April.
The new division aims to undertake innovative regenerative medicine studies and build an autonomous and highly agile research management structure, reporting directly to Astellas' Senior Vice-President and President of drug discovery research.
Its key priorities will be to establish and maintain technology platforms involving regenerative medicine and cell therapy, taking advantage of the multifunctional characteristics of cells to produce more effective treatments than are currently available.
Astellas stated last year that it would expand its presence in the regenerative medicine field, with its new cell therapy focus coming in addition to the conventional pharmaceutical research that it undertakes.
